Dissociable and common effects of methylphenidate, atomoxetine and citalopram on response inhibition neural networks

Neuropsychologia

Volumn 56, Issue 1, 2014, Pages 263-270

  Nandam, L Sanjay ^a   Hester, Robert ^b   Bellgrove, Mark A ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Atomoxetine; Citalopram; FMRI; Go no go; Methylphenidate; Response inhibition

Indexed keywords

ATOMOXETINE; CITALOPRAM; METHYLPHENIDATE; PLACEBO;

ADULT; ANGULAR GYRUS; ANTERIOR CINGULATE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; INFERIOR FRONTAL GYRUS; MALE; MENTAL TASK; MIDDLE FRONTAL GYRUS; NERVE CELL NETWORK; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RESPONSE INHIBITION; SINGLE DRUG DOSE; SUPERIOR TEMPORAL GYRUS; TASK PERFORMANCE; BOLD SIGNAL; BRAIN FUNCTION; DOPAMINERGIC SYSTEM; DRUG SPECIFICITY; ERROR AWARENESS TASK; EVENT RELATED POTENTIAL; GO NO GO TASK; INHIBITION CONSTANT; NERVE CONDUCTION; NORADRENERGIC SYSTEM; OCCIPITAL LOBE; PREGENUAL CINGULATE; SEROTONINERGIC SYSTEM;

ATOMOXETINE; CITALOPRAM; FMRI; GO NO-GO; METHYLPHENIDATE; RESPONSE INHIBITION;

ADOLESCENT; ADULT; AWARENESS; BRAIN; CITALOPRAM; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INHIBITION (PSYCHOLOGY); MAGNETIC RESONANCE IMAGING; MALE; METHYLPHENIDATE; NEURAL PATHWAYS; NEUROPSYCHOLOGICAL TESTS; NEUROTRANSMITTER AGENTS; OXYGEN; PROPYLAMINES; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84894251739     PISSN: 00283932     EISSN: 18733514     Source Type: Journal    
DOI: 10.1016/j.neuropsychologia.2014.01.023     Document Type: Article

References (62)

1. Aron A.R. From reactive to proactive and selective control: Developing a richer model for stopping inappropriate responses. Biological Psychiatry 2011, 69:e55-e68.
2. Aron A.R., Dowson J.H., Sahakian B.J., Robbins T.W. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry 2003, 54:1465-1468.
3. Aron A.R., Robbins T.W., Poldrack R.A. Inhibition and the right inferior frontal cortex. Trends in Cognitive Sciences 2004, 8:170-177.
4. Bellgrove M.A., Chambers C.D., Vance A., Hall N., Karamitsios M., Bradshaw J.L. Lateralized deficit of response inhibition in early-onset schizophrenia. Psychological Medicine 2006, 36:495-505.
5. Benke T., Delazer M., Bartha L., Auer A. Basal ganglia lesions and the theory of fronto-subcortical loops: Neuropsychological findings in two patients with left caudate lesions. Neurocase 2003, 9:70-85.
6. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biological Psychiatry 2006, 60:1111-1120.
7. Bond A., Lader M. The use of analogue scales in rating subjective feelings. British Journal of Medical Psychology 1974, 47:211-218.
8. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27:699-711.
9. Chamberlain S.R., Del Campo N., Dowson J., Muller U., Clark L., Robbins T.W., et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry 2007, 62:977-984.
10. Chamberlain S.R., Hampshire A., Muller U., Rubia K., Del Campo N., Craig K., et al. Atomoxetine modulates right inferior frontal activation during inhibitory control: A pharmacological functional magnetic resonance imaging study. Biological Psychiatry 2009, 65:550-555.
11. Chamberlain S.R., Muller U., Blackwell A.D., Clark L., Robbins T.W., Sahakian B.J. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006, 311:861-863.
12. Chamberlain S.R., Muller U., Cleary S., Robbins T.W., Sahakian B.J. Atomoxetine increases salivary cortisol in healthy volunteers. Journal of Psychopharmacology 2007, 21:545-549.
13. Chambers C.D., Bellgrove M.A., Stokes M.G., Henderson T.R., Garavan H., Robertson I.H., et al. Executive "brake failure" following deactivation of human frontal lobe. Journal of Cognitive Neuroscience 2006, 18:444-455.
14. Cox R.W. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Computer and Biomedical Research 1996, 29:162-173.
15. Crosbie J., Schachar R. Deficient inhibition as a marker for familial ADHD. American Journal of Psychiatry 2001, 158:1884-1890.
16. Del-Ben C.M., Deakin J.F., McKie S., Delvai N.A., Williams S.R., Elliott R., et al. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: An FMRI study. Neuropsychopharmacology 2005, 30:1724-1734.
17. Dockree P.M., Kelly S.P., Roche R.A., Hogan M.J., Reilly R.B., Robertson I.H. Behavioural and physiological impairments of sustained attention after traumatic brain injury. Brain Res Cogn Brain Res 2004, 20:403-414.
18. Eagle D.M., Bari A., Robbins T.W. The neuropsychopharmacology of action inhibition: Cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl) 2008, 199:439-456.
19. Eagle D.M., Tufft M.R., Goodchild H.L., Robbins T.W. Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berlin) 2007, 192:193-206.
20. Field C.A., O'Keefe G. Behavioral and psychological risk factors for traumatic injury. Journal of Emergency Medicine 2004, 26:27-35.
21. Finger G., Silva E.R., Falavigna A. Use of methylphenidate among medical students: A systematic review. Revista da Associação Médica Brasileira 2013, 59(3).
22. Gamo N.J., Wang M., Arnsten A.F. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49:1011-1023.
23. Gau S.S., Shang C.Y. Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. International Journal of Neuropsychopharmacology 2010, 13:243-256.
24. Graf H., Abler B., Freudenmann R., Beschoner P., Schaeffeler E., Spitzer M., et al. Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. Biological Psychiatry 2012, 69:890-897.
25. Henning J., Netter P. Oral application of citalopram (20mg) and its usefulness for neuroendocrine challenge tests. International Journal of Neuropsychopharmacology 2002, 5:67-71.
26. Hester R., Garavan H. Executive dysfunction in cocaine addiction: Evidence for discordant frontal, cingulate, and cerebellar activity. Journal of Neuroscience 2004, 24:11017-11022.
27. Hester R., Nandam L.S., O'Connell R.G., Wagner J., Strudwick M., Nathan P.J., et al. Neurochemical enhancement of conscious error awareness. Journal of Neuroscience 2012, 32:2619-2627.
28. Kamarck T.W., Haskett R.F., Muldoon M., Flory J.D., Anderson B., Bies R., et al. Citalopram intervention for hostility: Results of a randomized clinical trial. Journal of Consulting and Clinical Psychology 2009, 77:174-188.
29. Langenecker S.A., Kennedy S.E., Guidotti L.M., Briceno E.M., Own L.S., Hooven T., et al. Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biological Psychiatry 2007, 62:1272-1280.
30. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: Regional, laminar, and ultrastructural localization. Journal of Comparative Neurology 2001, 432:119-136.
31. Lou H.C., Rosa P., Pryds O., Karrebaek H., Lunding J., Cumming P., et al. ADHD: Increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow. Developmental Medicine & Child Neurology 2004, 46:179-183.
32. MacDonald A.W., Cohen J.D., Stenger V.A., Carter C.S. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science 2000, 288:1835-1838.
33. Macoveanu J., Hornboll B., Elliott R., Erritzoe D., Paulson O.B., Siebner H., et al. Serotonin 2 A receptors, citalopram and tryptophan-depletion: A multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology 2013, 38:996-1005.
34. Martins S., Tramontina S., Polanczyk G., Eizirik M., Swanson J.M., Rohde L.A. Weekend holidays during methylphenidate use in ADHD children: A randomized clinical trial. Journal of Child and Adolescent Psychopharmacology 2004, 14:195-206.
35. Menzies L., Achard S., Chamberlain S.R., Fineberg N., Chen C.H., del Campo N., et al. Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 2007, 130:3223-3236.
36. Michelson D., Adler L., Spencer T., Reimherr F.W., West S.A., Allen A.J., et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry 2003, 53:112-120.
37. Montgomery S.A. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: Studies with citalopram. International Clinical Psychopharmacology 1995, 10(Suppl. 1):S23-S27.
38. Montoya A., Hervas A., Cardo E., Artigas J., Mardomingo M.J., Alda J.A., et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Current Medical Research and Opinion 2009, 25:2745-2754.
39. Morrison J.H., Foote S.L., O'Connor D., Bloom F.E. Laminar, tangential and regional organization of the noradrenergic innervation of monkey cortex: Dopamine-beta-hydroxylase immunohistochemistry. Brain Research Bulletin 1982, 9:309-319.
40. Muller U., Suckling J., Zelaya F., Honey G., Faessel H., Williams S.C., et al. Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology (Berl) 2005, 180:624-633.
41. Murphy K., Garavan H. Deriving the optimal number of events for an event-related fMRI study based on the spatial extent of activation. Neuroimage 2005, 27:771-777.
42. Nandam L.S., Hester R., Wagner J., Cummins T.D., Garner K., Dean A.J., et al. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biological Psychiatry 2011, 69:902-904.
43. Nandam L.S., Hester R., Wagner J., Dean A.J., Messer C., Honeysett A., et al. Dopamine D(2) receptor modulation of human response inhibition and error awareness. Journal of Cognitive Neuroscience 2013, 25:649-656.
44. Nathan P.J., Stough C., Siteram G. Serotonin and information processing: A pharmacodynamic study on the effects of citalopram on cognitive and psychomotor function. Human Psychopharmacology 2000, 15:306-307.
45. Newcorn J.H., Kratochvil C.J., Allen A.J., Casat C.D., Ruff D.D., Moore R.J., et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry 2008, 165:721-730.
46. Overtoom C.C., Verbaten M.N., Kemner C., Kenemans J.L., van Engeland H., Buitelaar J.K., et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. Behavioural Brain Research 2003, 145:7-15.
47. Pauls A.M., O'Daly O.G., Rubia K., Riedel W.J., Williams S.C., Mehta M.A. Methylphenidate effects on prefrontal functioning during attentional-capture and response inhibition. Biological Psychiatry. 2012, 72(2):142-149.
48. Robinson E.S., Eagle D.M., Mar A.C., Bari A., Banerjee G., Jiang X., et al. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 2008, 33:1028-1037.
49. Rosa-Neto P., Lou H.C., Cumming P., Pryds O., Karrebaek H., Lunding J., et al. Methylphenidate-evoked changes in striatal dopamine correlate with inattention and impulsivity in adolescents with attention deficit hyperactivity disorder. Neuroimage 2005, 25:868-876.
50. Rubia K., Halari R., Cubillo A., Smith A.B., Mohammad A.M., Brammer M., et al. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 2011, 36:1575-1586.
51. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clinical Pharmacokinetics 2005, 44:571-590.
52. Schulz K.P., Fan J., Bedard A.C., Clerkin S.M., Ivanov I., Tang C.Y., et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Archives of General Psychiatry 2012, 69:952-961.
53. Spencer T., Biederman J., Wilens T.E., Faraone S.V. Adults with attention-deficit/hyperactivity disorder: A controversial diagnosis. Journal of Clinical Psychiatry 1998, 59(Suppl. 7):S59-S68.
54. Swick D., Ashley V., Turken U. Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks. Neuroimage 2011, 56:1655-1665.
55. Vaidya C.J., Austin G., Kirkorian G., Ridlehuber H.W., Desmond J.E., Glover G.H., et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14494-14499.
56. Vaidya C.J., Bunge S.A., Dudukovic N.M., Zalecki C.A., Elliott G.R., Gabrieli J.D. Altered neural substrates of cognitive control in childhood ADHD: Evidence from functional magnetic resonance imaging. American Journal of Psychiatry 2005, 162:1605-1613.
57. Vink M., Kahn R.S., Raemaekers M., van den Heuvel M., Boersma M., Ramsey N.F. Function of striatum beyond inhibition and execution of motor responses. Human Brain Mapping 2005, 25:336-344.
58. Vogt B.A., Hof P.R., Zilles K., Vogt L.J., Herold C., Palomero-Gallagher N. Cingulate area 32 homologies in mouse, rat, macaque and human: Cytoarchitecture and receptor architecture. Journal of Comparative Neurology 2013, 521:4189-4204.
59. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Angrist B., Hitzemann R., et al. Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. American Journal of Psychiatry 1997, 154:50-55.
60. Volkow N.D., Wang G.J., Newcorn J., Telang F., Solanto M.V., Fowler J.S., et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Archives of General Psychiatry 2007, 64:932-940.
61. Vollm B., Richardson P., Stirling J., Elliott R., Dolan M., Chaudhry I., et al. Neurobiological substrates of antisocial and borderline personality disorder: Preliminary results of a functional fMRI study. Criminal Behaviour and Mental Health 2004, 14:39-54.
62. Williams S.M., Goldman-Rakic P.S. Widespread origin of the primate mesofrontal dopamine system. Cerebral Cortex 1998, 8:321-345.